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Abstract
Background Studies on the expression of thymidylate syn-
thase (TS) in colorectal cancers (CRCs) have failed to provide
unequivocal prognostic or predictive information. Here, we
assessed the prognostic significance of TS expression in
Astler-Coller stage B2 and C CRCs defined by a p21WAF1/
p53 immunophenotype in patients subjected to 5-fluorouracil
(5FU)-based adjuvant therapy.
Methods A cohort of 189 CRCs was asssessed for TS,
p21WAF1 and p53 expression on tissue microarrays using
immunohistochemistry, and associations with disease-free
survival (DFS) and overall survival (OS) of the patients were
assessed using univariate and multivariate analyses.
Results TS expression led to the stratification of patients with
colon cancer, but not rectal cancer, with immunophenotypes
other than p21WAF1+/p53- (referred to as P&P) into subgroups
characterized by a worse (P&P TS+) and a better (P&P TS-)
DFS and OS, in univariate (P=0.006 and P=0.005, respective-
ly) and multivariate (P=0.0004 and P=0.002, respectively)
analyses. The p21WAF1+/p53- immunophenotype was associat-
ed with a favorable prognosis, irrespective of TS expression.
Conclusions The strong association observed between the
P&P TS+ immunophenotype and a worse DFS and OS sug-
gests a predictive significance of TS expression for 5FU-based
adjuvant therapy in patients with colon cancers exhibiting the
P&P immunophenotype. In addition, our findings suggest that
the appropriate target for assessment of TS expression as a
prognostic/predictive marker is a subgroup of colon cancers
with an immunophenotype other than p21WAF1+/p53-, and that
only in this subgroup high TS expression is associated with an
unfavorable DFS and OS. Therefore, we suggest that assessing
TS expression in conjunction with p21WAF1/p53 immuno-
phenotyping of colon cancers may improve the selection of
patients suitable for 5FU-based adjuvant chemotherapy.
Keywords Colorectal cancer . p21WAF1 . p53 . Thymidylate
synthase . 5FU-based therapy
1 Introduction
Significant progress in the systemic treatment of colorectal
cancer (CRC), attributed to the introduction of new drugs, has
not affected the efficacy of fluoropyrimidine analogs in che-
motherapy regimens where they are used as vehicles to im-
prove therapeutic responses. However, controversies remain
concerning indications for adjuvant therapy in stage II CRC
pateints. It has been argued that only one out of 25 patients
with stage II CRC may be cured by 5-flurouracil (5FU)-based
adjuvant chemotherapy [1]. Thus, there is a need to identify
predictive markers for 5FU-based chemotherapy responses.
The effect of 5FU-based therapy depends on the inhibition of
thymidylate synthase (TS), a key enzyme in nucleotide syn-
thesis, and a subsequent p53-dependent induction of apoptosis
through cell cycle regulatory proteins [2–4]. This notion,
corroborated by in vitro research using cell lines, has led to
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several clinical trials with the objective to determine the role
of TS in 5FU-based adjuvant chemotherapy. The results ob-
tained have, however, been discrepant and disappointing, and
have failed to provide unequivocal prognostic or predictive
information. Therefore, studies on the expression of TS in
CRC have been labeled as a “never-ending story” [5]. One
reason for this in limbo situation may be that, with the excep-
tion of p53 [6], the expression of important cell cycle regula-
tory proteins has not been considered in studies aimed at
identifying sugroups of patients in which TS could play a role.
Here, we assessed the prognostic significance of TS ex-
pression in patients with Astler-Coller stage B2 and C CRCs
defined by the p21WAF1/p53 immunophenotype and subjected
to 5FU-based adjuvant chemotherapy. Our findings suggest
that the appropriate target for assessment of TS expression as
prognostic/predictive marker is a subgroup of colon cancers
with an immunophenotype other than p21WAF1+/p53-, and
that only in this subgroup high TS expression is associated
with an unfavorable DFS and OS.
2 Materials and methods
2.1 Patients
The study group consisted of 189 nonselected, consecutive
patients who met the following criteria: (1) patients had un-
dergone potentially curative colorectal resection for sporadic
CRC (defined as absence of relevant family history at the time
of admission to the hospital), (2) distant metastases were
excluded upon preoperative liver ultrasonography, chest x-
ray, and during intraoperative exploration, (3) patients had
no chemotherapy prior to the operation, (4) patients had a
histopathologic diagnosis of invasive adenocarcinoma Astler-
Coller B2 or C, without involvement of resection margins, and
(5) patients received identical adjuvant 5FU-based therapy.
All available histological slides for all patients were re-
examined. In Table 1 the clinico-pathological details of the
189 tumors and patients are listed. The mean age of the
patients was 59.1 (range 33–81, median 60) years. Tumors
were resected at the Departments of Surgery of the Pomera-
nian Medical University teaching hospitals in Szczecin and
the Regional Oncological Center in Szczecin, Poland. The
operations consisted of either a resection with lymphadenec-
tomy or a total mesorectal excision for rectal carcinomas. All
patients (76 stage B2, and 113 stage C) were treated with the
same adjuvant chemotherapy regimen (six 5-day courses of
bolus infusions of 5FU [425 mg/m2] every four weeks com-
bined with leucovorin 20 mg/m2).
Forty out of 93 patients with rectal cancer received post-
operative radiotherapy (50.4 Gy) and 32 out of these patients
received preoperative radiotherapy (5×5 Gy). Of the 76
Astler-Coller stage B2 tumors 36 were rectal tumors and, of
these, 15 (42 %) received preoperative and 10 (28 %) postop-
erative radiotherapy. Since there were no statistically signifi-
cant differences in TS, p53, and p21WAF1 expression between
rectal cancers of patients who did or did not undergo preop-
erative radiotherapy, the former were included in the study
[TS (53.1 % vs. 62.7 %, respectively, P=0.38), p53 (65,6 %
vs. 69.5 %, respectively, P=0.81), and p21WAF1 (53.1 % vs.
66.1 %, respectively, P=0.26)].
The time from surgery until the time of death due to
cancer or to last known follow-up was regarded as OS, and
the time until the first appearance of a metastasis or a local
recurrence was regarded as DFS. The median follow-up
was 51 (mean, 51.1±23.8; range, 7–120) months. During
the follow-up, 43 of the 189 (22.8 %) patients died of their
disease and 115 (60.8 %) were alive without disease symp-
toms. Recurrences were found in 74 patients. Four patients
died of non-cancer related causes and were treated as
censored observations.
2.2 Tissue microarray construction
Tumor tissue was fixed in buffered 10 % formalin and embed-
ded in paraffin. Sections (4 μm thick) were stained with hema-
toxylin and eosin for histopathological diagnosis. Tissue micro-
arrays were constructed as previously described [7]. In short,
one 0.6 mm core was taken from a carefully identified, histo-
logically relatively homogenous, representative area with the
highest mitotic activity at the outer invasive zone of each CRC.
Table 1 Clinicopatholo-
gical characteristics of
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2.3 Immunohistochemistry
Tissue microarray slides were deparaffinized, rehydrated, and
endogenous peroxidase activity was blocked. Slides were im-
mersed in pH 9.0 buffer and heat-induced antigen retrieval was
performed in a pressure cooker (Pascal, DakoCytomation). The
slides were incubated for 30 min with the following monoclo-
nal antibodies: anti-p21WAF1 antibody (dilution 1:25), anti-
TS106 antibody (dilution 1:50; Chemicon, Temecula, USA),
and anti-p53 antibody (dilution 1:50). The slides were immu-
nostained using a Dako EnVision kit according to the manu-
facturer’s instructions (EnVision™ + Peroxidase Anti-mouse
Polymer labeled with horseradish peroxidase, Dako Co.,
Carpinteria, CA). We used the sensitive EnVision™ + visual-
ization system, since the detection system used is regarded as a
critically important variable in immunohistochemical analysis,
and since detection methods using signal amplification with
HRP-labeled polymers (such as EnVision™) have been shown
to be more sensitive than methods without such a layer of
amplification [7]. The reaction was developed with diamino-
benzidine substrate-chromogen solution, and the slides were
counterstained with hematoxylin. Appropriate positive and
negative controls were included. The immunohistochemical
procedures for all tissue microarrays encompassing all 189
tumors were performed at the same time under identical condi-
tions. Only four slides containing tissue cores from all 189
tumors were processed.
Immunohistochemistry for assessing the presence or ab-
sence of DNA mismatch repair (MMR) proteins was per-
formed on 185 CRCs (4 tumors could not be assessed due to
insufficient amount of tissue). Immunohistochemistry with
antibodies directed against MMR proteins has been regarded
as an equivalent for microsatellite instability (MSI) testing [8].
Defective DNA mismatch repair (dMMR) was assessed by
testing for loss of MLH1, MSH2, MSH6 and PMS2 expres-
sion. The following antibodies were used: anti-MLH1 (M1),
anti-MSH6 (44) (Ventana/Roche), anti-MSH2 (G2191129),
and anti-PMS2 (EPR3947) (Cell Marque) and the immuno-
histochemical reactions were performed in a Benchmark XT
(Ventana) automated immunohistochemical stainer according
to the manufacturer’s instructions. Loss of MMR protein
expression was defined as complete absence of nuclear stain-
ing in the presence of positive staining of stromal cells.
2.4 Scoring
Immunohistochemical staining for each tumor core was inde-
pendently assessed by two observers (PD and WD) who were
blinded to the clinical and pathological data. In cases of
disagreement, the result was reached by consensus. All tumor
cells in the core of the tissue microarray were counted, and the
percentage of tumor cell nuclei with unequivocal staining was
recorded for each core. p21WAF1 expression was classified as
negative (<1 % positive tumor nuclei, p21-) or positive (≥1 %
tumor cells showing nuclear immunoreactivity, p21+). For
assessement of p53 and TS expression, a histoscore system
was used. In this system, which was proved useful and repro-
ducible in assessing immunohistochemical staining, both av-
erage intensity and pattern scores were assessed [9, 10]. The
proportion of positive cells was estimated and given a score on
a scale from 1 to 6 (1=1% to 4%, 2=5 % to 19%, 3=20% to
39 %, 4=40 % to 59 %, 5=60 % to 79 %, and 6=80 % to
100 %). The average intensity of the positively stained tumor
cells was given a score ranging from 0 to 3 (0=no staining, 1=
weak staining, 2=intermediate staining, and 3=strong stain-
ing). A final score was then calculated by multiplying the
percentage score by the intensity score, to yield a minimum
value of zero and a maximum value of 18. A histoscore value
of 7 was adopted as a cut-off for stratification of p53 expres-
sion into low (≤ 7, p53-) and high (>7, p53+), because the
histogram of p53 values showed a local minimum at this point
that clearly divided the study population into two subgroups.
Similarly, stratification of TS expression into low (< 2, TS-)
and high (≥ 2, TS+) was based on a local minimum in the
histoscore histogram.
2.5 Statistics
Associations between the tumor immunophenotype and other
categorical variables were analyzed with Fisher’s exact test,
whereas the Mann–Whitney test was used for associations
with age. The Kaplan-Meier method was used for the univar-
iate survival analysis, and the differences between compared
groups were assessed by log-rank test. Cox’s proportional
hazards model was used for univariate and multivariate anal-
yses of factors associated with OS and DFS. The independent
variables included in the model were age, gender, tumor site,
Astler-Coller stage, histological grade, and the presence of
expression of the tumor markers studied. A value of P <0.05
was considered statistically significant. STATISTICA version
10 (StatSoft Inc., Tulsa, OK., USA) was used for the statistical
analyses. This study has been carried out according to RE-
MARK guidelines [11].
3 Results
3.1 TS, p53 and p21WAF1 expression, and correlation
with clinico-pathologic parameters
Immunohistochemical nuclear stainings were assessed using
the anti-p53 (Fig. 1a and b), anti-TS (Fig. 1c) and anti-p21
(Fig. 1d) antibodies. High p53 (p53+) nuclear expression
(histoscore p53 >7) was seen in 114 out of 189 samples
(60.3 %). The distribution of the p53 histoscores is shown in
Fig. 2. High TS (TS+) expression (histoscore TS ≥2) in tumor
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cell nuclei was noted in 127 out of 189 samples (67.2 %). The
distribution of the TS histoscores is shown in Fig. 3. Nuclear
expression of p21WAF1 (p21+) was noted in 126 out of 189
samples (66.7 %). The p21WAF1+/p53- immunophenotype
was found in 50 out of 185 samples (26.5 %). Loss of MMR
proteins was found in 31 out of 185 samples (16.8 %).
Next, the TS, p53, and p21WAF1 expression levels were
correlated with the following parameters: age and gender of
patients, tumor grade, stage and tumor site, and preoperative
radiotherapy. High TS expression in tumor cell nuclei was
seen more frequently in tumors located in the colon compared
to those in the rectum (75.0 % versus 59.1 %, P=0.03). High
p53 expression was seen more frequently in males than in
females (68.6 % versus 50.6 %, P=0.02). Expression of
p21WAF1 was seen more frequently in stage C than in stage
B2 CRCs (72.6 % versus 57.9 %, P=0.04). The p21WAF1+/
p53- immunophenotype was seen more frequently in females
than in males (34.5 % versus 19.6 %, P=0.03). No other
statistically significant associations were found.
3.2 Survival of patients with CRC defined by p21WAF1/p53
immunophenotype and TS expression
Univariate analysis in all patients (stage B2 + C) revealed that
high TS expression was associated with a significantly worse
OS (P=0.038, HR=2.26, 95 % CI 1.05–4.87). The association
with DFS did not reach significance (P=0.082, HR=1.59,
95 % CI 0.94–2.68). p21WAF1 expression was associated with
Fig. 1 p53, TS and p21
immunostaining of representative
colorectal cancer cores. a High
expression of p53 in nuclei of
tumor cells. b Marked fragment
of the core from Fig. 1a at high
magnification showing p53-
positive (brown) nuclei in almost
all cancer cells. c Low TS
expression (brown) in nuclei of
tumor cells. d p21 nuclear
expression in tumor cells
Fig. 2 Distribution of p53
histoscores in the study group
(n =189)
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a significantly better OS (P=0.0076, HR=0.44, 95 % CI 0.24–
0.81) and a borderline better DFS (P=0.076, HR=0.66, 95 %
CI 0.41–1.05), while high p53 expression was associated with a
significantly worse DFS (P=0.029, HR=1.74, 95 % CI 1.06–
2.87). The association with OS did not reach significance
(P=0.099, HR=1.73, 95 % CI 0.90–3.32). The p21WAF1+/
p53- (i.e., p21WAF1 expression and low p53) immunophenotype
was found to be associated with both a significantly better OS
(P=0.0057, HR=0.23, 95 % CI 0.08–0.65) and a significantly
better DFS (P=0.0023, HR=0.36, 95 % CI 0.18–0.69). For
combined phenotypes other than p21WAF1+/p53- (i.e.,
p21WAF1+/p53+, p21WAF1-/p53+, and p21WAF1-/p53-, collec-
tively defined as P&P, n =139), univariate analysis revealed a
significant association of high TS expression with a worse DFS
and OS (P=0.02, HR=1.90, 95 % CI 1.09–3.32 and P=0.009,
HR=2.99, 95 % CI 1.32–6.80, respectively).
Loss ofMMR protein expression was found to be associated
with a better DFS (P=0.01, HR=0.32, 95%CI 0.13–0.79), but
not a better OS (P=0.13). Multivariate analysis involving sex,
age, Astler-Coller stage, tumor grade, tumor site, TS expres-
sion, the p21WAF1/p53 immunophenotype and loss of MMR
protein expression identified Astler-Coller stage, high TS ex-
pression and the p21WAF1+/p53- immunophenotype as inde-
pendent factors associated with DFS and OS (Table 2). In this
analysis, the association of loss of MMR protein expression
with DFS did no longer reach statistical significance.
Kaplan-Meier survival curves showed that patients with the
p21WAF1+/p53- immunophenotype exhibited the best DFS and
OS (Figs. 4 and 5), but TS expression did not stratify these
subgroups (P=0.80 and P=0.85, respectively). However, TS
expression did stratify patients with the P&P phenotype into
two subgroups, which differed with respect to DFS and OS
(Figs. 4 and 5). The P&P TS + subgroup was associated with a
worse DFS (P=0.02) and OS (P=0.005) compared to the P&P
TS- subgroup. The P&P TS + curve also differed significantly
also from other curves, i.e., from the p21WAF1+/p53-TS + curve
and from the p21WAF1+/p53- TS- curve (Figs. 4 and 5), with
respect to DFS (P=0.0004 and P=0.02, respectively) and OS
(P=0.0003 and P=0.05, respectively). These findings were
confirmed in a multivariate analysis, which revealed an associ-
ation of the P&P TS + immunophenotype with a worse DFS
(P =0.0009, HR=2.27, 95 % CI 1.39–3.68) and OS
(P=0.0002, HR=3.82, 95 % CI: 1.89–7.73) compared to all
other immunophenotype combinations.
There are differences in therapeutic approaches between
cancers of the colon and the rectum. In order to assess whether
our results might depend on the site of the tumor, patients with
tumors localized in the colon and the rectum were analyzed
separately.
Colon Similar to the overall group of patients, we found that
TS expression did not significantly stratify patients with a
p21WAF1+/p53- immunophenotype, which was associated
with the best DFS and OS. However, TS expression did
stratify patients with tumors exhibiting the P&P phenotype
localized in the colon into two subgroups, which differed with
respect to DFS and OS (Figs. 6 and 7). The P&P TS+
subgroup was associated with a worse DFS (P=0.006) and
OS (P=0.005) compared to the P&P TS- subgroup. The P&P
TS+ curve differed significantly also from other curves, i.e.,
from the p21WAF1+/p53- TS+ curve and from the p21WAF1+/
p53- TS- curve (Figs. 6 and 7), with respect to DFS (P=
0.0005 and P=0.007, respectively) and OS (P=0.005 and
P=0.003, respectively). These findings were confirmed in
multivariate analyses, which showed an association of the
P&P TS + immunophenotype with a worse DFS (P =
0.0004, HR=4.93) and OS (P=0.002, HR=10.55) (Table 3)
compared to all other immunophenotype combinations. This
association remained significant (DFS: P=0.0008, HR=4.80,
95% CI 1.92–12.03; OS: P=0.004, HR=8.82, 95% CI 1.99–
Fig. 3 Distribution of TS
histoscores in the study group
(n =189)
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39.03) when cases with loss of MMR protein expression were
excluded from the analysis.
Rectum In patients with rectal cancer, (n =93) no significant
association was found between the P&P/TS+ immuno-
phenotype and DFS (P=0.29 for univariate and P=0.41 for
multivariate analysis, respectively) or OS (P=0.07 for univar-
iate and P=0.23 for multivariate analysis, respectively). The
percentage of tumors exhibiting the P&P/TS+ immuno-
phenotype did not differ significantly between patients who
did or did not undergo preoperative radiotherapy (56.3 %
versus 52.5 % respectively, P=0.82). There was significant
interaction between the site of the tumor (colon versus rectum)
and the P&P/TS+ immunophenotype with respect to an asso-
ciation with DFS (P=0.01) and OS (P=0.03) in a multivariate
analysis. These findings indicate that only patients with colon
cancer (but not those with rectal cancer) treated with adjuvant
5FU could be stratified into better or worse prognostic
subgroups by TS expression when the p21WAF1/p53
immunophenotype was considered.
4 Discussion
5FU-based adjuvant chemotherapy reduces the risk of recur-
rence by 41 % and the overal death rate by 33 % of stage C
CRC patients [12]. In stage II CRC, this type of chemotherapy
improves the 5-year survival rate by a mere 3–6 % [13]. In
advanced CRC improvements in survival obtained with vari-
ous treatments (e.g. 5FU plus leucovorin, 5FU plus metho-
trexate) have remained limited, even in cases where initial
response rates were substantially improved [14, 15]. Hence, it
appears that a sizable percentage of patients will not benefit
from 5FU-based adjuvant chemotherapy, but neverthesless
will be exposed to the toxic effects of this treatment [16].
Table 2 Multivariate analysis of
disease-free (DFS) and overall
(OS) survival of stage B2 and C
colorectal cancer patients
(n =185) treated with 5FU-based
adjuvant chemotherapy
* p21+p53-=expression of




Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
Male Sex 1.27 (0.77–2.09) 0.36 1.39 (0.73–2.68) 0.32
Age 1.01 (0.93–1.03) 0.60 1.00 (0.97–1.03) 0.98
Astler-CollerC 2.46 (1.43–4.25) 0.001 2.69 (1.28–5.61) 0.009
Grade 3 1.51 (0.93–2.46) 0.09 1.94 (1.01–3.70) 0,046
Site Rectum 0.97 (0.61–1.64) 0.99 0.85 (0.45–1.61) 0,61
High TS 1.73 (1.01–2.95) 0.045 2.39 (1.09–5.23) 0.03
p21+p53-* 0.36 (0.18–0.72) 0.004 0.19 (0.07–0.57) 0.003
MMRp loss** 0.41 (0.16–1.06) 0.07 0.71 (0.24–2.11) 0.54
Fig. 4 DFS of patients with stage
B2+C colorectal carcinomas (n =
189) categorized according to TS
expression. TS stratifies patients
with P&P immunophenotype
(i.e., p21+/p53+, p21-/p53-and
p21−/p53+): P&P TS + versus
P&P TS-curves, P=0.02. The
P&P TS + curve differs also from
other curves, i.e., from the p21+/
p53−TS + curve (P=0.0004) and
from the p21+/p53−TS− curve
(P=0.02). TS does not
significantly stratifiy patients with
a p21+/p53− immunophenotype
(P=0.80). p21=p21WAF1
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Therefore, it is important to better define subgroups of CRC
patients who will benefit from 5FU-based treatment and those
who will not. Previously, we have shown that expression of
p21WAF1 in colorectal tumor cells identifies a subgroup of
Astler-Coller stage B2 patients who may significantly benefit
from 5FU-based chemotherapy. This, thus, allows a better
selection of patients for adjuvant chemotherapy [17]. In this
report, we show that TS expression analysis, in conjunction
with p21WAF1/p53 immunophenotyping, allows the identifi-
cation of prognostic subgroups of CRC patients subjected to
5FU-based adjuvant chemotherapy.
We found a high nuclear TS expression in 67.2 % of the
CRC samples, which is in agreement with the findings ofWong
et al. (69 %) [18]. TS is one of the principle enzymes involved
in DNA synthesis, and serves as a molecular target of 5FU [19].
TS also exhibits properties of an oncogene [20]. The multidi-
rectional mechanism of action of 5FU includes an inhibition of
TS and a direct interference with DNA and RNA synthesis
through incorporation of 5-fluoronucleotides [2]. In vitro stud-
ies using CRC cell lines have suggested a predictive importance
of TS expression with respect to the efficacy of 5FU-based
chemotherapy [21]. However, clinical trials assessing the
predictive/prognostic significance of TS expression in CRC
patients have reported discrepant findings. Meta-analyses re-
vealed a moderately negative impact of high TS expression on
the survival of patients with CRC [22], and a slightly negative
Fig. 5 OS of patients with stage
B2+C colorectal carcinomas (n =
189) categorized according to TS
expression. TS stratifies patients
with a P&P immunophenotype
(i.e., p21+/p53+, p21−/p53− and
p21−/p53+): P&P TS + versus
P&P TS− curves, P=0.005. The
P&P TS + curve differs also from
other curves, i.e., from the p21+/
p53-TS + curve (P=0.0003) and
from the p21+/p53−TS− curve
(P=0.05). TS does not
significantly stratifiy patients with
a p21+/p53− immunophenotype
(P=0.85). p21=p21WAF1
Fig. 6 DFS of patients with stage
B2+C colon carcinoma (n=96)
categorized according to TS
expression. TS stratifies patients
with a P&P immunophenotype
(i.e., p21+/p53+, p21−/p53− and
p21−/p53+): P&P TS + versus
P&P TS− curves, P=0.006. The
P&P TS + curve differs also from
other curves, i.e., from the p21+/
p53-TS + curve (P=0.0005) and
from the p21+/p53−TS− curve
(P=0.007). TS does not
significantly stratifiy patients with
a p21+/p53− immunophenotype.
p21=p21WAF1
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correlation of TS expression with a response to 5FU [23]. It was
concluded that, in clinical practice, TS expression alone could
not be used as a predictivemarker [23]. Hence, despite the well-
documented role of TS as a target for 5FU-based therapy, it
failed to enter the clinic as a useful predictive marker for the
response to 5FU (for literature review see [24–26]). Using CRC
cell lines, it has been suggested that resistance to 5FU chemo-
therapy cannot be assigned solely to TS or p53 expression [27].
Recent data indicated a need for including cell cycle-associated
parameters in the search for predictive markers beneficial for
5FU-based chemotherapy in CRC [6, 28]. It seems, therefore,
reasonable to assume that several factors, rather than one (i.e.,
TS), should be considered in order to identify CRC subgroups
sensitive to 5FU treatment.
Through multivariate analysis we observed no significant
association between TS expression alone and DFS or OS.
However, when the p21WAF1/p53 phenotype was taken into
account, it was only in the subgroup of patients with colon
cancer and an immunophenotype other than p21WAF1+/p53-
that TS expression emerged as an important prognostic/
predictive marker. High TS expression in a subgroup of patients
with colon cancer characterized by phenotypes other than
p21WAF1+/p53- was associated with a poor DFS and OS. Thus,
the expression of these markers may provide prognostic/
predictive information on the outcome of 5FU-based chemo-
therapy. Considering the subgroup of patients with colon cancer
exhibiting phenotypes other than p21WAF1+/p53-, it seems that
those with a low TS expression may more likely benefit from
5FU-based adjuvant therapy, whereas those with a high TS
expression may not benefit because they already exhibit poor
DFS and OS rates, despite having received 5FU-based therapy.
On the other hand, TS expression did not stratify patients with
colon cancer characterized by the best prognostic immuno-
phenotype, i.e., p21WAF1+/p53-, with respect to either DFS or
OS. Hence, for this subgroup of patients TS expression should
not be expected to act as a prognostic/predictive marker for
5FU-based adjuvant therapy.
Patients with rectal cancer treated with adjuvant 5FU could
not be stratified into better or worse prognostic subgroups by
TS expression when the p21WAF1/p53 immunophenotype was
considered. One cannot exclude the possibility that pre- and
postoperative radiotherapy may affect the results beyond
Fig. 7 OS of patients with stage
B2 + C colon carcinoma (n =96)
categorized according to TS
expression. TS stratifies patients
with a P&P immunophenotype
(i.e., p21+/p53+, p21−/p53− and
p21−/p53+): P&P TS + versus
P&P TS− curves, P=0.005. The
P&P TS + curve differs also from
other curves, i.e., from the p21+/
p53-TS + curve (P=0.005) and
from the p21+/p53− TS− curve
(P=0.003). TS does not
significantly stratifiy patients with
a p21+/p53-immunophenotype.
p21=p21WAF1
Table 3 Multivariate analysis of
disease-free (DFS) and overall
(OS) survival of stage B2 and C
colon cancer patients (n =94)
treated with 5FU-based adjuvant
chemotherapy
*MMRp = mismatch repair
proteins
Parameters DFS OS
Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
Male Sex 1.24 (0.58–2.64) 0.58 1.68 (0.61–4.58) 0.32
Age 1.01 (0.98–1.05) 0.53 1.01 (0.96–1.06) 0.74
Astler-Coller C 2.28 (1.03–5.07) 0.04 1.76 (0.67–4.68) 0.25
Grade 3 1.63 (0.79–3.36) 0.19 1.08 (0.42–2.79) 0.88
P&P/TS+ 4.93 (2.03–11.93) 0.0004 10.55 (2.36–47.30) 0.002
MMRp loss* 0.37 (0.08–1.65) 0.19 0.33 (0.04–2.63) 0.88
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p21WAF1/p53 and TS expression. It could also downstage
rectal cancer and/or the result may be site-specific. Currently,
this problem remains unresolved and requires further study on
larger groups of patients.
Several clinical studies have focused on associations of the
p21WAF1/p53 immunophenotype alone with survival, with dis-
crepant results [29–33]. In agreement with our study, several
investigators have reported the shortest survival for patients
with p21WAF1-/p53+ tumors and the longest for patients with
p21WAF1+/p53- tumors [31, 32]. However, others reported the
best prognosis for low p21WAF1 expression combined with high
p53 expression [29, 33]. Ropponen et al. [30] failed to show a
correlation between the p21WAF1/p53 immunophenotype and
survival. These discrepancies may, at least partially, be attribut-
ed to the heterogenous groups of patients studied, i.e., the stage
and type of adjuvant therapy, as well as the small sizes of the
subgroups in the studies. However, they may also reflect the
multifunctional activity of the p53-p21WAF1 cell cycle check-
point pathway [34]. It is well known that p53 and its down-
stream target p21WAF1 are essential for maintaining genomic
stability. Our results suggest that the effect of 5FU-based treat-
ment of patients with CRCmay depend on the status of the p53-
p21WAF1 pathway. Patients with tumors with a functional p53-
p21WAF1 pathway (p21WAF1+/p53-) exhibited the best survival,
irrespective of TS expression (i.e., presumably irrespective of
5FU-based adjuvant therapy–which is directed against TS–
since the therapy could not improve the prognosis of this a
priori best prognostic subgroup). In other words, patients in this
subgroup could not benefit from 5FU-based adjuvant therapy
because they have already had the best prognosis. On the other
hand, if the p53-p21WAF1 pathway was impaired (presumably
in the P&P subgroup comprising p21WAF1+/p53+, p21WAF1-/
p53+ or p21WAF1-/p53- tumors) then only survival of patients
with tumors exhibiting low TS expression could be improved
by this type of adjuvant treatment.
In our study, both the p21WAF1/p53 immunophenotype and
loss of MMR protein expression were found to act as prog-
nostic indicators for DFS in univariate analyses. However,
only the former retained statistical significance in a multivar-
iate analysis. Therefore, the p21WAF1/p53 immunophenotype
seems to be a better predictor of DFS than loss of MMR
protein expression in patients with stage B and C Astler-
Coller CRC subjected to adjuvant 5FU-based therapy. Simi-
larly, although both mutant TP53 and MSI-H were found to
be prognostic indicators for DFS in univariate analyses, only
TP53 retained statistical significance in multivariate analyses
[35]. These results further underscore the importance of the
p53-p21WAF1 cell cycle checkpoint pathway for the prognosis
of patients with CRC treated with 5FU-based therapy.
Wewould also like tomention some limitations of this study.
First, this is a retrospective study and the series of patients
is rather small. Therefore, our results should be confirmed by
further prospective randomized trials. Second, the choice of cut-
off levels requires a short comment. For p21WAF1 we used a cut-
off level of ≥1 %. In line with our previous report [17], such a
cut-off for a positive p21WAF1 expression was associated with a
better DFS and OS of patients with CRC. Since there are no
generally accepted cut-off levels for p53 or TS protein nuclear
expression, we tested several local minima (present on histo-
grams) and we have chosen those which gave the strongest
associations with survival. Various threshold levels have been
used in the assessment of immunohistochemical p53 expression
in CRC. In 14 reports on the prognostic significance of immu-
nohistochemical assessment of p53 accumulation in CRC, cut-
off levels ranging from >0 % to >20 % have been applied and,
consequently, the percentage of p53 positive tumors ranged
from 30 % to 63 % [36]. In other reports cut-off levels of
25 % [37], >50 % [38] or ≥50 % [39] have been used, yielding
63 %, 48.5 % and 43 % of p53 positive tumor cells, respec-
tively. With our cut-off level (histoscore p53>7), high p53
(p53+) nuclear expression was seen in 60.3 % of the samples,
which is within the range found in the literature. A number of
different scoring methods and threshold levels have been re-
ported for the assessment of immunohistochemical TS expres-
sion in colorectal cancer: (1) The intensity of TS staining of
tumors was arbitrarily graded from 0 to 3 (or 0 to 4) and
dichotomized (grades 0 to 1 defined as low level, and 3 to 4
as high level of TS expression) – a review of 13 studies [22] and
[24, 26, 40, 41], (2) TS expression was dichotomized using
arbitrary thresholds of 10 %, 15 %, 20 % [22] or ≥30 % [42] of
stained cells per field, (3) Histoscores were calculated [18, 43].
In these reports the proportion of cases expressing high levels of
TS ranged from 14 % to 80 %. We found 67.2 % of CRCs
exhibiting high TS expression, which is again within the range
found in the literature.
Currently, it is not known what percentage of tumor cells has
to be positive for thosemarkers to affect the biology of a tumor in
such a way that it can influence the survival of patients subjected
Fig. 8 Schematic algorithm for determining the prognostic significance
of nuclear TS expression in patients with stage B2 + C colon cancer
subjected to 5FU-based adjuvant chemotherapy
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to adjuvant 5FU-based therapy. Therefore, cut-off levels are
usually chosen empirically (e.g. 5 %, 10 %, 20 %, 50 %).
However, it seems that a histoscore (which we applied in this
study) better reflects biologic associations than amere percentage
count. Wong et al. [18] showed that assessment of TS expression
with the use of a histoscore showed statistical differences be-
tween patients with CRC responding and non-responding to
5FU-based therapy, whereas when only the percentage of posi-
tively stained nuclei was assessed no differences were found. In
that report a median histoscore was used as a threshold level. In
our studywe used a cut-off close tomedian. Interestingly,Munro
et al. [44] in a review based on 168 reports, including survival
data of 18.766 patients, assessing p53 abnormalities and clinical
outcomes in colorectal cancer found “no evidence for any rela-
tionship between the criterion used to define ‘positive’ by im-
munohistochemistry and outcome”. They noted, for example,
that the absolute survival rate difference was 13.4 % when the
criterion was set at >1 % cells positive, and 13.5 % when a cut-
off value of >10 % positivity was used.
The major advantage of immunohistochemistry on tissue
microarrays is that a large number of tumors can be assessed
simultaneously under identical laboratory conditions, which
improves the reproducibility of the results. A limitation of this
technology, however, is that small cores transferred from donor
to recipient paraffin blocks may not be representative of the
entire tumor. Therefore, sampling a typical and representative
region of a tumor is themost important step in tissue microarray
construction. Here, we employed one core from a carefully
identified, histologically relatively homogenous, representative
area exhibiting the highest mitotic activity at the outer invasive
front of each CRC. With this approach, we found high expres-
sion of p53 in 60.3 %, high TS expression in 67.2 %, and
p21WAF1 expression in 66.7 % of CRCs, which is within the
range reported for these proteins in the literature (30 %–63 %
for p53, 15–80 % for TS and 16 %–87 % for p21WAF1).
There are divergent opinions on the number of cores required
to establish associations between biomarkers and clinicopatho-
logical parameters. Hoos et al. [45] reported that correlations
between phenotypes and clinical outcome did not significantly
differ between full sections and triplicate 0.6–mm core tissue
microarrays. These correlations were, however, not significantly
different when only one 0.6-mm core tissue microarray was used
[46, 47]. Zhang et al. [46] reached >97 % concordance rates
between tissue microarrays and full sections for several markers,
and they concluded that “a tissue microarray with a single core
per specimen ensures full biological representativeness to identi-
fy associations between biomarkers and clinicopathological pa-
rameters, with no significantly associated sampling bias”. Clearly
the lower the heterogeneity of the tumor cells with respect to the
proteins under study, the better the concordance of tissue micro-
arrays with the whole sections. Wong et al. [18] tested
intratumoral variation of TS nuclear expression in CRCs and
found it to be rather small (maximum difference in TS histoscore
of 15when a range from 0 to 300was applied). Barely noticeable
intratumor heterogeneity of TS expression was noted in another
report [42]. However, the key step in the construction of tissue
microarrays remains careful sampling of representative tumor
regions. According to Zhang et al. [46] “The biopsy of 0.6 mm
in diameter taken from a typical and representative region of the
tumor provides a reliable and efficient system for large-scale
analysis of cancer tissues on tissue microarray platforms and is
useful for large-scale clinicopathological studies, conserving the
molecular profile of the molecular markers that are clinically
relevant”.
We conclude that (1) the p21WAF1+/p53- immunophenotype
is associated with a favorable prognosis in patients with stage
B2 + C colon cancer treated with 5FU-based chemotherapy,
regardless of the level of TS expression, (2) TS expression
stratifies patients with colon cancer exhibiting immunophe-
notypes other than p21WAF1+/p53- and treated with 5FU in
two subgroups characterized by a worse (high TS expression)
and a better (low TS expression) prognosis. The observed
strong association of the P&P TS+ immunophenotype with a
worse DFS in both univariate and multivariate analyses sug-
gests the predictive significance of TS expression for 5FU-
based adjuvant therapy in patients with colon cancer exhibiting
the P&P immunophenotype. Finally, (3) the results of this study
suggest that future clinical trials evaluating the predictive sig-
nificance of TS expression in colon cancer for 5FU-based
adjuvant chemotherapy should take the p21WAF1/p53
immunophenotype of the tumor cells into account. Therefore,
we propose a summarizing algorithm (depicted in Fig. 8) as a
starting point for clinical trials assessing the predictive signifi-
cance of TS expression in patients with stage B2 + C colon
cancer subjected to 5FU-based adjuvant chemotherapy. Since
this is a retrospective study, our results should be confirmed in
additional prospective randomized studies.
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